Axonics Stock Forecast, Price & News

Axonics (NASDAQ:AXNX) Frequently Asked Questions

Is Axonics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Axonics stock.
View analyst ratings for Axonics or view top-rated stocks.

What stocks does MarketBeat like better than Axonics?

Wall Street analysts have given Axonics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Axonics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Axonics' next earnings date?

Axonics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Axonics.

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) announced its earnings results on Wednesday, August, 4th. The company reported ($0.59) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.10. The business earned $45.87 million during the quarter, compared to analyst estimates of $39.24 million. Axonics had a negative net margin of 45.36% and a negative trailing twelve-month return on equity of 18.01%.
View Axonics' earnings history.

How has Axonics' stock price been impacted by COVID-19?

Axonics' stock was trading at $30.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AXNX stock has increased by 114.5% and is now trading at $64.83.
View which stocks have been most impacted by COVID-19.

What guidance has Axonics issued on next quarter's earnings?

Axonics issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $186 million-$188 million, compared to the consensus revenue estimate of $178.80 million.

What price target have analysts set for AXNX?

7 brokerages have issued 1 year price objectives for Axonics' shares. Their forecasts range from $57.00 to $79.00. On average, they expect Axonics' share price to reach $69.56 in the next year. This suggests a possible upside of 7.3% from the stock's current price.
View analysts' price targets for Axonics or view top-rated stocks among Wall Street analysts.

Who are Axonics' key executives?

Axonics' management team includes the following people:

• Raymond Wayne Cohen, Chief Executive Officer & Director (LinkedIn Profile)
• Danny L. Dearen, President & Chief Financial Officer (LinkedIn Profile)
• Rinda K. Sama, Chief Operating Officer (LinkedIn Profile)
• Guang Qiang Jiang, Chief Technology Officer
• Karen Noblett, Chief Medical Officer

What is Raymond W. Cohen's approval rating as Axonics' CEO?

12 employees have rated Axonics CEO Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among Axonics' employees.

Who are some of Axonics' key competitors?

Some companies that are related to Axonics include Hill-Rom (HRC), Penumbra (PEN), Globus Medical (GMED), Tandem Diabetes Care (TNDM), ShockWave Medical (SWAV), Inspire Medical Systems (INSP), Integra LifeSciences (IART), ICU Medical (ICUI), Nevro (NVRO), Merit Medical Systems (MMSI), Inari Medical (NARI), Haemonetics (HAE), The Beauty Health (SKIN), AtriCure (ATRC) and NuVasive (NUVA).
View all of AXNX's competitors.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include Raytheon Technologies (RTX), Honeywell International (HON), (OAS), Pfizer (PFE), The Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

(AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Axonics' stock symbol?

Axonics trades on the NASDAQ under the ticker symbol "AXNX."

Who are Axonics' major shareholders?

Axonics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (12.67%), BlackRock Inc. (7.12%), Credit Suisse AG (5.65%), Lord Abbett & CO. LLC (4.85%), RTW Investments LP (4.21%) and Vanguard Group Inc. (3.97%). Company insiders that own Axonics stock include Alfred J Ford Jr, Alfred J Ford, Jr, Andera Partners, Bakker Juliet Tammenoms, Danny L Dearen, John Woock, Raphael Wisniewski, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends for Axonics.

Which major investors are selling Axonics stock?

AXNX stock was sold by a variety of institutional investors in the last quarter, including Ziegler Capital Management LLC, Bank of America Corp DE, C WorldWide Group Holding A S, Balyasny Asset Management LLC, JPMorgan Chase & Co., Goldman Sachs Group Inc., Federated Hermes Inc., and Invesco Ltd.. Company insiders that have sold Axonics company stock in the last year include Alfred J Ford Jr, Danny L Dearen, John Woock, Raymond W Cohen, Rinda Sama, and Robert E Mcnamara.
View insider buying and selling activity for Axonics or view top insider-selling stocks.

Which major investors are buying Axonics stock?

AXNX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Macquarie Group Ltd., Millennium Management LLC, BlackRock Inc., Frontier Capital Management Co. LLC, Amundi, Vanguard Group Inc., and Dimensional Fund Advisors LP.
View insider buying and selling activity for Axonics or or view top insider-buying stocks.

How do I buy shares of Axonics?

Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axonics' stock price today?

One share of AXNX stock can currently be purchased for approximately $64.83.

How much money does Axonics make?

Axonics has a market capitalization of $2.99 billion and generates $111.54 million in revenue each year. The company earns $-54,920,000.00 in net income (profit) each year or ($1.48) on an earnings per share basis.

How many employees does Axonics have?

Axonics employs 416 workers across the globe.

What is Axonics' official website?

The official website for Axonics is www.axonics.com.

Where are Axonics' headquarters?

Axonics is headquartered at 26 TECHNOLOGY DRIVE, IRVINE CA, 92618.

How can I contact Axonics?

Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at (866) 722-5738 or via email at [email protected].